期刊文献+

RPN2与肝癌患者预后及对肝癌细胞生长的作用 被引量:3

Prognostic Value of RPN2 in Hepatocellular Carcinoma and Its Effect on the Growth of Hepatocellular Carcinoma Cells
原文传递
导出
摘要 目的:探讨核糖蛋白2(ribophorin II,RPN2)在肝细胞肝癌(HCC)组织中的表达和对HCC患者生存的影响,同时分析RPN2对肝癌HepG2细胞生长和克隆形成的作用。方法:应用免疫组化方法和HCC公共芯片数据,从蛋白和m RNA水平检测HCC组织中RPN2的表达,同时分析RPN2与HCC患者临床参数的关系及预后相关性;进一步利用MTS法和克隆形成实验在肝癌HepG2细胞中检测RPN2对细胞生长的作用。结果:98例肝癌组织中,RPN2阳性表达率88.78%,对应癌旁肝组织中,RPN2阳性表达率74.49%;癌组织中RPN2染色评分为5.80±3.15,癌旁肝组织RPN2染色评分为2.13±1.59,肝癌组织中RPN2表达显著上调(P<0.001)。3个肝癌公共芯片数据(共522例肝癌)中RPN2的m RNA表达水平同样显著升高(均P<0.001)。98例肝癌患者RPN2表达水平与肿瘤直径(P=0.004)、门脉侵袭(P=0.012)和TNM分期(P=0.009)相关;RPN2高表达的患者总体生存期(OS)和无复发生存期(RFS)较RPN2低表达的患者短(OS:P=0.027;RFS:P=0.036)。肝癌HepG2细胞转染RPN2小干扰RNA后,细胞生长能力显著受抑制。结论:RPN2在肝癌中表达显著升高,RPN2的表达与肝癌的恶性进展有关,RPN2显著促进肝癌细胞生长。 Objective: To explore the expression of Ribophorin II(RPN2) in hepatocellular carcinoma(HCC) and its effect on the survival of HCC patients, and to analyze the effects of RPN2 on the growth of HepG2 cells. Methods: The protein and m RNA expression of RPN2 in HCC patients was analyzed by immunohistochemical(IHC) staining and public data of HCC, and to analyze its relationship between the expression of RPN2 and clinicopathological features and prognosis of HCC patients. The effects of RPN2 on the growth of HCC cells were detected by using MTS and cloning formation experiment in HepG2 cells. Results: In 98 HCC tissues, the RPN2 positive expression rate was 88.78%, and the RPN2 positive expression rate was 74.49% in the para-carcinoma tissue. The RPN2 staining score was 5.80±3.15 in HCC tissue, and the RPN2 staining score was 2.13 ±1.59 in the para-carcinoma tissue, the expression of RPN2 in HCC was significantly increased(P<0.001). The expression of RPN2 m RNA in three public data of HCC(522 cases) was also significantly increased(All P<0.001). RPN2 expression was related to tumor diameter(P=0.004), portal vein invasion(P=0.012) and TNM staging(P=0.009) in 98 HCC patients. The overall survival(OS) and recurrence-free survival(RFS) of HCC patients with high expression of RPN2 were shorter than those with RPN2 low expression(OS: P=0.027;RFS: P=0.036). The cell growth was significantly inhibited with the transfection of RPN2 si RNA in HepG2 cells. Conclusion: The expression of RPN2 in HCC was significantly increased,and the expression of RPN2 was related to the progression of HCC. RPN2 promoted HCC cell growth.
作者 答秀维 张蓓 尚芸 王琳 张洪新 赵超 DA Xiu-wei;ZHANG Bei;SHANG Yun;WANG Lin;ZHANG Hong-xin;ZHAO Chao(Departement of Pain Treatment,Second Affiliated Hospital,the Fourth Military Medical University,Xi'an,Shaanxi,710038,China;Departement of Neurology,Second Affiliated Hospital,the Fourth Military Medical University,Xi'an,Shaanxi,710038,China)
出处 《现代生物医学进展》 CAS 2020年第8期1425-1430,共6页 Progress in Modern Biomedicine
基金 国家自然科学基金项目(81772934,81802345)。
关键词 RPN2 预后 生长 肝细胞肝癌 RPN2 Prognosis Growth HCC
  • 相关文献

参考文献2

二级参考文献126

  • 1Giuseppe Cabibbo,Marcello Maida,Chiara Genco,Pietro Parisi,Marco Peralta,Michela Antonucci,Giuseppe Brancatelli,Calogero Cammà,Antonio Craxì,Vito Di Marco.Natural history of untreatable hepatocellular carcinoma:A retrospective cohort study[J].World Journal of Hepatology,2012,4(9):256-261. 被引量:11
  • 2Mike SL Liem,Ronnie TP Poon,Chung Mau Lo,Wai Kuen Tso,Sheung Tat Fan.Outcome of transarterial chemoembolization in patients with inoperable hepatocellular carcinoma eligible for radiofrequency ablation[J].World Journal of Gastroenterology,2005,11(29):4465-4471. 被引量:15
  • 3Alexander J. Thompson,Andrew J. Muir,Mark S. Sulkowski,Dongliang Ge,Jacques Fellay,Kevin V. Shianna,Thomas Urban,Nezam H. Afdhal,Ira M. Jacobson,Rafael Esteban,Fred Poordad,Eric J. Lawitz,Jonathan McCone,Mitchell L. Shiffman,Greg W. Galler,William M. Lee,Robert Reindollar,John W. King,Paul Y. Kwo,Reem H. Ghalib,Bradley Freilich,Lisa M. Nyberg,Stefan Zeuzem,Thierry Poynard,David M. Vock,Karen S. Pieper,Keyur Patel,Hans L. Tillmann,Stephanie Noviello,Kenneth Koury,Lisa D. Pedicone,Clifford A. Brass,Janice K. Albrecht,David B. Goldstein,John G. McHutchison.Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus[J]. Gastroenterology . 2010 (1)
  • 4Llovet Josep M,Ricci Sergio,Mazzaferro Vincenzo,Hilgard Philip,Gane Edward,Blanc Jean-Frédéric,de Oliveira Andre Cosme,Santoro Armando,Raoul Jean-Luc,Forner Alejandro,Schwartz Myron,Porta Camillo,Zeuzem Stefan,Bolondi Luigi,Greten Tim F,G.Sorafenib in advanced hepatocellular carcinoma. The New England Quarterly . 2008
  • 5B Taouli,DM Koh.Diffusion-weighted MR imaging of the liver. Radiology . 2010
  • 6Pugh R N,Murray-Lyon I M,Dawson J L,Pietroni M C,Williams R.Transection of the oesophagus for bleeding oesophageal varices. The British journal of surgery . 1973
  • 7Ann-Lii Cheng,Yoon-Koo Kang,Zhendong Chen,Chao-Jung Tsao,Shukui Qin,Jun Suk Kim,Rongcheng Luo,Jifeng Feng,Shenglong Ye,Tsai-Sheng Yang,Jianming Xu,Yan Sun,Houjie Liang,Jiwei Liu,Jiejun Wang,Won Young Tak,Hongming Pan,Karin Burock,Jessie Zou,Dimitris Voliotis,Zhongzhen Guan.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial[J].Lancet Oncology.2009(1)
  • 8Riccardo Lencioni,Josep Llovet.Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma[J].Semin Liver Dis.2010(01)
  • 9Shukui Qin,Yuxian Bai,Ho Yeong Lim,Sumitra Thongprasert,Yee Chao,Jia Fan,Tsai-Shen Yang,Vajarabhongsa Bhudhisawasdi,Won Ki Kang,Yu Zhou,Jee Hyun Lee,Yan Sun.Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia[J].Journal of Clinical Oncology.2013(28)
  • 10Vincenzi Bruno,Santini Daniele,Russo Antonio,Addeo Raffaele,Giuliani Francesco,Montella Liliana,Rizzo Sergio,Venditti Olga,Frezza Anna Maria,Caraglia Michele,Colucci Giuseppe,Del Prete Salvatore,Tonini Giuseppe.Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. The Oncologist . 2010

共引文献54

同被引文献29

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部